Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
Year: 2022
Type: article
Source: Blood
Authors: Anne Ségolène Cottereau, Louis Rebaud, Judith Trotman, Pierre Feugier, Loretta J. Nastoupil, Emmanuel Bachy, Ian W. Flinn, Corinne Haioun, Loic Ysebaert, Nancy L. Bartlett, Hervé Tilly, René-Olivier Casasnovas, Romain Ricci, Cedric Portugues, Irène Buvat, Michel Meignan, Franck Morschhauser
Institutions: Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Inserm, Institut Curie, Concord Hospital, Concord Repatriation General Hospital, Centre Hospitalier Régional et Universitaire de Nancy, The University of Texas MD Anderson Cancer Center, Hospices Civils de Lyon, Hôpital Lyon Sud, Sarah Cannon, Tennessee Oncology, Université Paris-Est Créteil, Hôpitaux Universitaires Henri-Mondor, Institut universitaire du cancer de Toulouse Oncopole, Washington University in St. Louis, Centre Henri Becquerel, CHU Dijon Bourgogne, The Lymphoma Academic Research Organisation, Centre Hospitalier Universitaire Henri-Mondor, Lymphoma Study Association, Centre Hospitalier Universitaire de Lille
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310106576